Long-term avelumab in advanced non-small-cell lung cancer: summaries and <i>post hoc</i> analyses from JAVELIN Solid Tumor.

Within this subset, a slight trend was observed for a higher frequency of some disease characteristics potentially associated with less aggressive disease compared with those who received <2 years of avelumab treatment, which included a better performance status, smaller tumor burden, a lower prevalence of liver metastases at baseline and a higher frequency of disease control achieved with prior chemotherapy.

also in 4,078 other papers